Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms

  • Hong-lin ZHU ,
  • Qian DU ,
  • Wei-lin CHEN ,
  • Xiao-xia ZUO ,
  • Quan-zhen LI ,
  • Si-jia LIU
Expand
  • Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha 410008, China

Received date: 2019-01-11

  Online published: 2019-09-03

Supported by

Supported by the National Natural Science Foundation of China(81671622);Supported by the National Natural Science Foundation of China(81771765);Hunan Provincial Natural Science Fundation(2018JJ3823)

Abstract

Objective: To analyze the expression profile of serum cytokines in patients with systemic sclerosis (SSc) and explore its possible regulatory mechanisms.Methods: Serum and DNA of peripheral blood mononuclear cells were collected from 30 SSc patients and 80 normal controls (NCs). According to the presence or absence of interstitial lung disease (ILD) in SSc, the patients were divided into SSc with ILD group and SSc without ILD group. According to the degree of skin involvement, the patients were divided into diffuse systemic scleroderma (dcSSc) group and limited systemic scleroderma (lcSSc) group. According to the presence of anti-topoisomerase-1 antibody (anti-Scl-70 antibody) in the serum of patients with SSc, they were divided into SSc Scl-70 (+) group and SSc Scl-70 (-) group. 27 cytokines in serum were detected by Luminex MAGPIX detection system and Bio-Plex Pro Human Cytokine 27-plex Assay kit: interleukin-1β (IL-1β), interleukin-1 receptor antagonist (IL-1ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12P70, IL-13, IL-15, IL-17, basic fiber growth factor (BASIC FGF), eotaxin, granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interferon-γ (IFN-γ), interferon-gamma induced protein 10(IP-10), monocyte chemotactic protein 1(MCP-1), macrophage inflammatory protein-1α(MIP-1α), macrophage inflammatory protein 1β(MIP-1β), platelet-derived growth factor BB (PDGF-BB), regulated on activation in normal T-cell expressed and secreted (RANTES), tumor necrosis factor-α (TNF-α), and vascular endothelial growth factor(VEGF). Methylation sites were detected by Illumina 450K methylation chip.Results: Compared with NCs group, the expression of 12 cytokines (BASIC FGF, eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1ra, IL-6, IP-10, MCP-1, TNF-α and RANTES) in the SSc group significantly increased (P<0.05), IL-5 was decreased expression in the SSc group (P<0.05), there was no signi-ficant difference in the expressions of the other 14 cytokines. Compared with lcSSc group, 9 cytokines (eotaxin, IL-5, MCP-1, IL-2, RANTES, IL17A, IL-8, MIP-1β and PDGF-BB) increased in dcSSc group, but there was no significant difference. Compared with SSc without ILD group, IL-15 increased in SSC with ILD group [18.2(172.97) ng/L vs. 2.03(0.05) ng/L, P<0.05]. Compared with SSc Scl-70 (-) group, the expression of IP-10 decreased in SSc Scl-70 (+) group [1 030 (2 196.6) ng/L vs. 1 878 (2 964) ng/L, P<0.05]. The correlation analysis of serum cytokines with erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) showed that IL-6 was positively correlated with ESR (r =0.04, P= 0.017), MCP-1 (r= 0.49, P= 0.043) and MIP-1β (r= 0.41, P= 0.007) positively correlated with CRP. By analyzing the changes of methylation sites of cytokines, it was found that cg17744604 in IL-10 TSS1500 region, cg06111286 in IL-12P70 TSS200 region, cg07935264 in IL-1 β TSS200 region, cg01467417 in IL-1ra TSS1500 region, cg03989987 in IL-1ra 5'UTR region and cg21099624 in VEGF TSS200 region were all hypomethylated.Conclusion: There were different cytokines expression profiles in the serum of SSc patients, and the altered cytokines were correlected with the degree of skin damage and pulmonary fibrosis. Many cytokines were regulated by methylation.

Cite this article

Hong-lin ZHU , Qian DU , Wei-lin CHEN , Xiao-xia ZUO , Quan-zhen LI , Si-jia LIU . Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms[J]. Journal of Peking University(Health Sciences), 2019 , 51(4) : 716 -722 . DOI: 10.19723/j.issn.1671-167X.2019.04.021

References

[1] Denton CP, Khanna D . Systemic sclerosis[J]. Lancet, 2017,390(10103):1685-1699.
[2] Allanore Y, Simms R, Distler O , et al. Systemic sclerosis[J]. Nat Rev Dis Primers, 2015: 15002.( 2015-04-23)[2018-12-01]. .
[3] LeRoy EC, Black C, Fleischmajer R , et al. Scleroderma (syste-mic sclerosis): classification, subsets and pathogenesis[J]. J Rheumatol, 1988,15(2):202-205.
[4] Bhattacharyya S, Wei J, Varga J . Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities[J]. Nat Rev Rheumatol, 2011,8(1):42-54.
[5] Raja J, Denton CP . Cytokines in the immunopathology of systemic sclerosis[J]. Semin Immunopathol, 2015,37(5):543-557.
[6] Dantas AT, Almeida AR, Sampaio M , et al. Different profile of cytokine production in patients with systemic sclerosis and association with clinical manifestations[J]. Immunol Lett, 2018,198:12-16.
[7] Zhu H, Zhu C, Mi W , et al. Integration of genome-wide DNA methylation and transcription uncovered aberrant methylation-regulated genes and pathways in the peripheral blood mononuclear cells of systemic sclerosis[J]. Int J Rheumatol, 2018:7342472.(2018-09-02)[2018-12-11]. .
[8] Masi AT . Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee[J]. Arthritis Rheum, 1980,23(5):581-590.
[9] Burska A, Boissinot M , Ponchel F. Cytokines as biomarkers in rheumatoid arthritis[J]. Mediators Inflamm, 2014: 545493.( 2014-03-09)[2018-12-22]..
[10] Needleman BW, Wigley FM, Stair RW . Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma[J]. Arthritis Rheum, 1992,35(1):67-72.
[11] Hasegawa M, Fujimoto M, Kikuchi K , et al. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis[J]. J Rheumatol, 1997,24(2):328-332.
[12] Hasegawa M, Fujimoto M, Matsushita T , et al. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis[J]. Clin Rheumatol, 2011,30(2):231-237.
[13] Wuttge DM, Wildt M, Geborek P , et al. Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease[J]. Arthritis Res Ther, 2007,9(5):R85.
[14] Takada T, Ohashi K, Hayashi M , et al. Role of IL-15 in interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibody[J]. Respir Med, 2018,141:7-13.
[15] Antonelli A, Ferri C, Fallahi P , et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis: a longitudinal study[J]. Rheumatology (Oxford), 2008,47(1):45-49.
[16] Goser S, Ottl R, Brodner A , et al. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy[J]. Circulation, 2005,112(22):3400-3407.
[17] Feinberg AP . The key role of epigenetics in human disease prevention and mitigation[J]. N Engl J Med, 2018,378(14):1323-1334.
[18] McInnes IB, Buckley CD, Isaacs JD . Cytokines in rheumatoid arthritis-shaping the immunological landscape[J]. Nat Rev Rheumatol, 2016,12(1):63-68.
[19] van der Heijde D, Cheng-Chung Wei J, Dougados M , et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial[J]. Lancet, 2018,392(10163):2441-2451.
[20] Chen Z, Bozec A, Ramming A , et al. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis[J]. Nat Rev Rheumatol, 2019,15(1):9-17.
Outlines

/